• 主页
  • 查找结果
  • A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.

A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.

Chinese medical journal (2012-08-31)
Hai-Bo Wei, Jing Hu, Li-Hua Shang, Yun-Yan Zhang, Fei-Fei Lu, Min Wei, Yan Yu
摘要

Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum with different ERCC1 C118T/ MDR1 C3435T single-nucleotide polymorphism (SNP). Relevant studies were identified by searching the PubMed, Embase, Cochrane, OVID, Springer, EBSCO and CNKI databases. Inclusion criteria were patients with advanced NSCLC who received platinum-based chemotherapy, an evaluated polymorphism of ERCC/MDR1 and overall response rate. We excluded duplicate publications, letters and review articles. The RevMan 4.2 and STATA 11 package were used to do comprehensive quantitative assessment. A total of 11 studies were included in this meta-analysis. For studies evaluating ERCC1 C118T, test for heterogeneity was done (χ(2) = 13.41, P = 0.1), and the odds ratio (OR) for the wild-type C/C genotype versus the heterozygous C/T and T/T genotypes was 1.50 (95% CI 1.09 - 2.06, P = 0.01). In four studies evaluating MDR1 polymorphism, test for heterogeneity was also done (χ(2) = 3.22, P = 0.36), and the OR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotypes was 2.30 (95% CI 1.44 - 3.68, P = 0.0005). The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T and MDR1 C3435T SNP. In further perspective studies, the ERCC1/MDR1 SNPs might serve as simple and less invasive biomarkers for personalized chemotherapy with platinum-based anticancer drugs.

材料
货号
品牌
产品描述

Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂黑, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder, 99.995% trace metals basis
Sigma-Aldrich
铂, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
铂, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.10 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder, ≤10 μm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂黑, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.076 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.125-0.135 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Sigma-Aldrich
铂, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
铂, wire, diam. 0.127 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.20 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.127 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, powder (coarse), 99.99% trace metals basis
Sigma-Aldrich
铂黑, low bulk density, ≥99.9% trace metals basis
铂, wire reel, 0.1m, diameter 1.0mm, annealed, may be used as one component of a thermocouple, 99.99%
铂, wire reel, 1m, diameter 0.3mm, annealed, may be used as one component of a thermocouple, 99.99%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。